Table 1:

Demographics and Baseline Characteristics

	ROS1-positive NSCLC with no prior ROS1 inhibitor	ROS1-positive NSCLC with a prior ROS1 inhibitor
	Total (N = 71)	Total (N = 56)
Age (years)
Median	57.0	57.0
Min, Max	28, 80	33, 78
Sex, n (%)
Female	43 (60.6)	38 (67.9)
Male	28 (39.4)	18 (32.1)
Race, n (%)
Asian	48 (67.6)	27 (48.2)
White	18 (25.4)	25 (44.6)
Black or African American	1 (1.4)	1 (1.8)
Native Hawaiian or Other Pacific Islander	1 (1.4)	1 (1.8)
Not Reported/Unknown	3 (4.2)	2 (3.6)
Ethnicity, n (%)
Hispanic or Latino	3 (4.2)	1 (1.8)
Not Hispanic or Latino	68 (95.8)	53 (94.6)

Source: U.S. Food and Drug Administration. NDA Multi-disciplinary Review and Evaluation and Approval packages, repotrectinib.²¹